Pulse Biosciences Stock (NASDAQ:PLSE)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$24.99

52W Range

$12.56 - $28.53

50D Avg

$22.93

200D Avg

$18.38

Market Cap

$1.86B

Avg Vol (3M)

$308.59K

Beta

1.66

Div Yield

-

PLSE Company Profile


Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

75

IPO Date

May 18, 2016

Website

PLSE Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22
Cycle Units Products$140.00K

Fiscal year ends in Dec 25 | Currency in USD

PLSE Financial Summary


Dec 25Dec 24Dec 23
Revenue---
Operating Income$-76.94M$-56.26M$-43.57M
Net Income$-72.78M$-53.59M$-42.21M
EBITDA$-76.94M$-55.08M$-42.37M
Basic EPS$-1.08$-0.92$-0.88
Diluted EPS$-1.08$-0.92$-0.88

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26May 07, 26 | 12:00 AM
Q4 25Feb 20, 26 | 4:30 PM
Q3 25Nov 05, 25 | 4:30 PM

Peer Comparison


TickerCompany
LFMDLifeMD, Inc.
KMTSKestra Medical Technologies, Ltd.
BBNXBeta Bionics, Inc.
IMTXImmatics N.V.
ATAIAtai Beckley Inc.
NKTRNektar Therapeutics
STAASTAAR Surgical Company
OPKOPKO Health, Inc.
NVCRNovoCure Limited
DNTHDianthus Therapeutics, Inc.